The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure

Bibliography

• LEVINE TB, FRANCIS GS, GOLDSMITH SR et al.: Activity of the sympathetic nervous system and renin-angiotensin system and their relationship to hemodynamic abnormalities in congestive heart failure. Am. I Cardiol (1982) 49:1659–1666.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, COHN JN, JOHNSON G et al: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation (1993) 87:40–48.
   Google Scholar
• WEBER KT, SUN Y, KATAWA LC: Wound healing following myocardial infarction. Clin. Cardiol (1996) 19:447–455.
   PubMed Web of Science ®Google Scholar
• CARSON PE: Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am. Heart J. (2000) 140:361–366.
   PubMed Web of Science ®Google Scholar
• BENEDICT CR, FRANCIS GS, JOHNSTONE DE etal.: For the SOLVD Investigators. Effect of long term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am. I Cardiol. (1995) 75:1151–1157.
   Google Scholar
• BRUNNER-LA ROCCA HP, VADDADI G, ESLER MD: Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. I Am. Coll. Cardiol (1999) 33(5):1163–1173.
   PubMed Web of Science ®Google Scholar
• ROIG E, PEREZ-VILLA F, MORALES M et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur. Heart (2000) 21:53–57.
   PubMed Web of Science ®Google Scholar
• PITT B: Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc. Drugs Ther. (1995) 9:145–149.
   PubMed Web of Science ®Google Scholar
• LEE WH, PACKER M: Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation (1986) 73:257–267.
   PubMed Web of Science ®Google Scholar
• STRUTHERS AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur. Heart J. (1995) 16(Suppl. N):103–106.
   Google Scholar
• URATA H, KINOSHITA A, MISONO KS etal.: Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. j Biol. Chem. (1990) 265:22348–22357.
   Google Scholar
• LIU YH, YANG XP, SHAROV VG et al:Effects of angiotensin converting enzyme inhibitors and angiotensin II Type I receptor antagonists in rats with heart failure. Role of kinins and angiotensin II Type II receptors. j Clin. Invest. (1997) 90:1926–1935.
   Google Scholar
• RIEGGER GA, BOUZO H, PETR P et al.: For the STRETCH investigators: Improvement of exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224–2230.
   PubMed Web of Science ®Google Scholar
• GRANGER CB, ERTL G, KUCH J et al: For the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) investigators randomized trial of candesartan cilexetil in the treatment of congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart 1. (2000) 139:609–617.
   PubMed Web of Science ®Google Scholar
• MATSUMORI A: On behalf of the assessment of response to candesartan in heart failure in Japan (ARCH-fl study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur. j Heart Fail. (2003) 5:669–677.
   Google Scholar
• CROZIER I, IKRAM H, ARVAN N et al.:For the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation (1995) 91:691–697.
   Google Scholar
• HAVRANEK EP, THOMAS I, SMITH WB etal.: For the Irbesartan Heart Failure Group. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. j Am. Coll Cardiol. (1999) 33:1174–1181.
   Google Scholar
• MAZAYEV VP, FOMINA IG, KAZAKOV EN et al.: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int. j. Cardiol (1998) 65:239–246.
   PubMed Web of Science ®Google Scholar
• FLATHER M, YUSUF S, KOBER L etal.:Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE Inhibitor Myocardial Collaborative Group. Lancet (2000) 355:1575–1581.
   Google Scholar
• LANG RM, ELKAYAM U, YELLEN LG et al: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. j. Am. Coll Cardiol. (1997) 30:983–1017.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, CHANG P, WILLENHEIMER R et al.: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. j. Am. Coll Cardiol. (1995) 26:438–445.
   PubMed Web of Science ®Google Scholar
• McKELVIE RS, YUSUF S, PERICAK D et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: the RESOLVD Pilot Study Investigators. Circulation (1999) 100:1056–1064.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al: On behalf of the ELITE study investigators. Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• McDONALD KM, MOCK J, D'ALOIA A et al.: Bradykinin antagonism inhibits the anti-growth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation (1995) 91:2043–2048.
   Google Scholar
• TONKON M, AWAN N, NIAZI I et al: A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int.Pict. (2000) 54:11–18.
   PubMed Web of Science ®Google Scholar
• MURDOCH DR, McDONAGH TA, FARMER R et al: ADEPT: Addition of the ATi receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. Am. Heart j (2001) 141:800–807.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANAND I, COHEN IS etal.: For the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short-term and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation (1999) 99:2658–2664.
   Google Scholar
• HAMROFF G, KATZ SD, MAN CINI Detal.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99: 990–992.
   Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R etal.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - The Losartan Heart Failure Survival Study (ELITE II). Lancet (2000) 355:1582–1587.
   Google Scholar
• COHN JN, TOGNONI G: For the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. j. Med. (2001) 345:1667–1675.
   Google Scholar
• ••This is the first study to demonstrate thatan ARB in combination with ACE inhibitor therapy results in a reduction of hospitalisations.
   Google Scholar
• DICKSTEIN K, KJEKSHUS J, OPTIMAAL STEERING COMMITTEE: For the OPTIMAAL Study Group. Effects of Losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet (2002) 360:752–760.
   Google Scholar
• SWEDBERG K, PFEFFER M, GRANGER C etal.: Candesartan in heart failure. Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. j. Card. Fail. (1999) 5(3):276–282.
   Google Scholar
• PFEFFER MA, MCMURRAY J, VELAZQUES EJ et al: For the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. j. Med. (2003) 349:1893–1906.
   Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM - Overall programme. Lancet (2003) 362:759–766.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated the use ofcandesartan in patients with clinical heart failure, regardless of ejection fraction, and resulted in a reduction of all-cause mortality, cardiovascular mortality and HF hospitalisations.
   Google Scholar
• McMURRAY JJV, STERGREN J, SWEDBERG K et al.: For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM - Added trial. Lancet (2003) 362:767–771.
   Google Scholar
• ••This study demonstrated the addition ofcandesartan to optimal HF treatment (including ACE-inhibitor and 3-blocker treatment) and resulted in a further reduction of both cardiovascular mortality and HF hospitalisations.
   Google Scholar
• GRANGER CB, McMURRAY JJV, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated that patientsintolerant of ACE inhibitors could tolerate an ARB and also that the ARB candesartan resulted in a reduction of cardiovascular mortality and HF hospitalisations.
   Google Scholar
• YUSUF S, PFEFFER MA, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet (2003) 362:777–781.
   PubMed Web of Science ®Google Scholar
• ••This is the first study to demonstrate areduction in HF hospitalisations with ARB for patients with HF-PSE It also demonstrated a decrease in the incidence of diabetes mellitus.
   Google Scholar
• McKELVIE RS, ROULEAU J-L, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur. Heart J. (2003) 24:1727–1734.
   PubMed Web of Science ®Google Scholar
• GAVRAS I, GAVRAS H: Are patients who develop angioedema with ACE inhibitor at risk of the same problem with ATi receptor blockers? Arch. Intern. Med. (2003) 163:240–241.
   Web of Science ®Google Scholar
• TRESCH DD, McGOUGH MF: Heart failure with normal systolic function: A common disorder in older people. J. Am. Ceriam Soc. (1995) 43:1035–1042.
   Web of Science ®Google Scholar
• McKELVIE RS, BENEDICT CR, YUSUF S: Prevention of congestive heart failure and treatment of asymptomatic left ventricular dysfunction. In: Evidence-Based Cardiology (2nd Ed.). S Yusuf, JA Cairns, AJ Cam, EL Fallen, BJ Gersh (Eds), British Medical Journal Books (2003):643–658.
   Google Scholar
• THE TASK FORCE OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY: The treatment of heart failure. Eur. Heart J. (1997) 18:736–753.
   PubMed Web of Science ®Google Scholar
• TENDERA M: Ageing and heart failure:the place of ACE inhibitors in heart failure with preserved systolic function. Eur. Heart J. (2000) 2:18–114.
   Google Scholar
• YUSUF, S, GERSTEIN H, HOOGWERF B et al: Ramipril and the development of diabetes. JAMA (2001) 286:1882–1885.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al: For the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet (2002) 359:995-1003 Affiliation Robert S McKelvie MD, PhD, FRCPC Hamilton Health Sciences (General Site), 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada Tel: +1 905 572 7155; Fax: +1 905 577 1480; E-mail: [email protected]
   Google Scholar